Assessment of pulmonary function test in type 2 diabetes mellitus and its correlation with their HbA1c levels

Authors

  • Archana Toppo Department of Medicine, Pt. J.N.M. Medical College, Dr. B.R.A.M Hospital, Raipur, Chhattisgarh, India
  • Kulvant Singh Ajamani Department of Medicine, Pt. J.N.M. Medical College, Dr. B.R.A.M Hospital, Raipur, Chhattisgarh, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20190109

Keywords:

Diabetes mellitus, HbA1c, Pulmonary function test

Abstract

Background: Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia and deranged metabolism of carbohydrates, lipids and protein that result from insensitivity to endogenous insulin. It is a substantial global health problem and markedly increases morbidity and mortality of the affected people.

Methods: The present study was conducted in the Department of medicine Dr. B.R.A.M. Hospital, Raipur. Total 67 subjects with type II diabetes mellitus as per WHO criteria of diabetes mellitus, aged between 18-60years of both sexes were included in the study. Patients FBS, PPBS were analysed by glucose oxidase (GOD), peroxidase (POD) methods in ILAB 650 analyser and HbA1C was analysed using HPLC. Pulmonary function test was conducted in all the subjects using the spirometer which is the gold standard for accurate and repeatable measurement of lung function.

Results: Majority of the subjects were male (36, 53.7%) and belonged to age group of 51-60years (n=34, 50.7%), Duration of DM </=10years (n=47, 70.1%), restrictive pulmonary function in 10 (14.9%) subjects. Correlation of age with a restrictive pattern of PFT (P=0.013*) and with duration of diabetes (P<0.0001**). Pulmonary function test parameters having mild downstream correlation with diabetes mellitus.

Conclusions: Diabetes was more common in the sixth decade of life with slight male preponderance. The short-term indicators of glycaemic controls were not significantly associated with a restrictive pattern of PFT. Despite the best effort, there are limitations of this study, which includes small sample size, author have not taken general population, and lack of a control group. These limitations can be overcome in the future studies.

References

American Diabetes Association. Standards of medical care in diabetes-2012. Diab Care. 2012;35(1):S11-63.

King H, Aubert RE, Herman WH. Global burden of diabetes: prevalence, numerical estimates, and projections. Diab Care. 1998;21(9):1414-31.

Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diab Endocrinol. 2017;5(8):585-96.

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The wisconsin epidemiologic study of diabetic retinopathy: II. prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520-6.

Aronson D. Hyperglycemia and the pathobiology of diabetic complications. In: Fisman EZ, Tenenbaum A, eds. Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Karger: 2008;45:1-16.

Emerging risk factors collaboration. diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.

Borch-Johnsen K, Neil A, Balkau B, Larsen S, Nissinen A, Pekkanen J, et al. Glucose tolerance and cardiovascular mortality-comparison of fasting and 2hr diagnostic criteria, the DECODE study group: glucose tolerance and cardiovascular mortality comparison of fasting and 2hr diagnostic criteria. Arch Inter Med. 2001;161:397-405.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.

Walter RE, Beiser A, Givelber RJ, O'connor GT, Gottlieb DJ. Association between glycemic state and lung function: the Framingham Heart Study. Am J Resp Critical Care Med. 2003;167(6):911-6.

Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diab. 2001;50(10):2384-9.

Aronson D. Hyperglycemia and the pathobiology of diabetic complications. In: Fisman E.Z., Tenenbaum A, eds. Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Karger: 2008;45:1-16.

Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle diabetes study. Diab Res Clin Prac. 2000;50:153-9.

Van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a meta-analysis. Chest. 2010;138(2):393-406.

Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) study. Diab Care. 2008;31(4):741-6.

Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle diabetes study. Diab Care. 2004;27(3):752-7.

Benbassat CA, Stern E, Blum I, Kramer M, Lebzelter J, Fink G. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127-32.

Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S. Pulmonary function tests in type 2 diabetes mellitus and their association with glycaemic control and duration of the disease. Lung India: Off Organ Ind Chest Soc. 2013;30(2):108.

Acharya PR, D’Souza M, Anand R, Kotian SM. Pulmonary function in type 2 diabetes mellitus: correlation with body mass index and glycemic control. Inter J Sci Study. 2016;3(11):18-23.

Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle diabetes study. Diab Res Clin Prac. 2000;50:153-9.

Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Brancati FL. Vital capacity as a predictor of incident type 2 diabetes: the atherosclerosis risk in communities’ study. Diab Care. 2005;28(6):1472-9.

Sinha S, Guleria R, Misra A, Pandey RM. Pulmonary functions in patients with type 2 diabetes mellitus and correlation with anthropometry and microvascular complications. Ind J Med Res. 2004;119(2):66.

Mori H, Okubo M, Okamura M, Yamane K, Kado S, Egusa G, et al. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Inter Med. 1992;31(2):189-93.

Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527-32.

Marvisi M, Bartolini L, del Borrello P, Brianti M, Marani G, Guariglia A, et al. Pulmonary function in non-insulin-dependent diabetes mellitus. Respiration. 2001;68(3):268-72.

Ljubić S, Metelko Ž, Car N, Roglić G, Dražić Z. Reduction of diffusion capacity for carbon monoxide in diabetic patients. Chest. 1998;114(4):1033-5.

Downloads

Published

2019-01-23

Issue

Section

Original Research Articles